ArticleCureus2025
Benralizumab in Corticosteroid-Refractory Drug Reaction With Eosinophilia and Systemic Symptoms: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Research advances on the role of eosinophils in acute liver injury].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe hypersensitivity reaction involving multiple organ systems. While high-dose systemic corticosteroids are the first-line treatment, some cases are refractory, and effective second-line options are limited. We report a case of a 20-year-old male with lamotrigine-induced DRESS, presenting with rash, fever, eosinophilia, and fulminant hepatic failure unresponsive to corticosteroids. Following a single subcutaneous dose of benralizumab, an interleukin-5 (IL-5) receptor monoclonal antibody, the patient exhibited rapid clinical and laboratory improvement, narrowly avoiding liver transplantation. Benralizumab has demonstrated efficacy in corticosteroid-refractory DRESS cases, often achieving resolution with a single dose. This case supports the potential role of IL-5 axis blockade as a promising therapeutic strategy in managing severe DRESS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.